UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class: |
Trading Symbol(s): |
Name of Exchange on Which Registered: | ||
| “ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02 | Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
This Current Report on Form 8-K/A of Lyell Immunopharma, Inc. (the “Company”) amends the Company’s Current Report on Form 8-K dated September 29, 2021 and filed with the Securities and Exchange Commission on September 30, 2021 (the “Original Filing”) to correct a typo referring to the date on which Dr. Richard Klausner will no longer be an employee of the Company. On September 29, 2021, Dr. Klausner informed the Company that he will be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2021.
Except as described herein, no other changes have been made to the Original Filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lyell Immunopharma, Inc. | ||||||
| Dated: October 1, 2021 | ||||||
| By: | /s/ Heather Turner | |||||
| Heather Turner | ||||||
| Chief General Counsel | ||||||
Document and Entity Information |
Sep. 29, 2021 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001806952 |
| Document Type | 8-K/A |
| Document Period End Date | Sep. 29, 2021 |
| Entity Registrant Name | LYELL IMMUNOPHARMA, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-40502 |
| Entity Tax Identification Number | 83-1300510 |
| Entity Address, Address Line One | 201 Haskins Way |
| Entity Address, City or Town | South San Francisco |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94080 |
| City Area Code | (650) |
| Local Phone Number | 695-0677 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.0001 per share |
| Trading Symbol | LYEL |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | true |
| Amendment Description | This Current Report on Form 8-K/A of Lyell Immunopharma, Inc. (the “Company”) amends the Company’s Current Report on Form 8-K dated September 29, 2021 and filed with the Securities and Exchange Commission on September 30, 2021 (the “Original Filing”) to correct a typo referring to the date on which Dr. Richard Klausner will no longer be an employee of the Company. On September 29, 2021, Dr. Klausner informed the Company that he will be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2021. Except as described herein, no other changes have been made to the Original Filing. |
-8?2
M0$3;8T.P6BP^0"X99K>]9!:G